MAGELLAN LONGEVITY
HomeResearchStudy library › Can transcranial photobiomodulation (t-PBM) improve cognition, mood…
Study summary · Brain, cognition & mood

Can transcranial photobiomodulation (t-PBM) improve cognition, mood, and biomarker levels in individuals with mild cognitive impairment (MCI)?

In one paragraph

Transcranial PBM Helmet, a randomized trial in 93 older adults (J Photochem Photobiol B 2024, PMID 39423445) — the t-PBM group showed significantly improved cognition (MoCA scores) compared to placebo (p=0.0301), with delta values of 3.20 for t-PBM and 1.97 for placebo. The abstract does not specify other limitations.

Source: J Photochem Photobiol B 2024, PMID 39423445 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

J Photochem Photobiol B · 2024 · PMID 39423445 · DOI 10.1016/j.jphotobiol.2024.113041

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Near-infrared light therapy to the brain improved cognitive function and increased a neuroplasticity biomarker in older adults with mild cognitive impairment.

The question

Can transcranial photobiomodulation (t-PBM) improve cognition, mood, and biomarker levels in individuals with mild cognitive impairment (MCI)?

What they tested

Transcranial photobiomodulation (t-PBM) will improve cognition scores, depression, anxiety, resilience scores, and neuroplasticity biomarkers, while not altering neurodegeneration biomarkers, in individuals with MCI compared to a placebo.

How they did it

A total of 93 older adults with MCI were randomized to either a t-PBM (n=47) or placebo (n=46) group. Clinical assessments and serum biomarker measurements (BDNF, NSE, S100B) were conducted at baseline, 60 days post-treatment, and a 150-day follow-up. Intervention effects were analyzed using repeated measures two-way ANOVA, Tukey post hoc test, Fischer's exact test, and Generalized Estimating Equations.

What they found

76 individuals completed the study (t-PBM: 40, placebo: 36). The t-PBM group showed significantly improved cognition (MoCA scores) compared to placebo (p=0.0301), with delta values of 3.20 for t-PBM and 1.97 for placebo. This cognitive improvement persisted until the three-month follow-up and was accompanied by increased BDNF levels in the t-PBM group (p=0.0046), with delta values of 821.94 for t-PBM and 359.41 for placebo. t-PBM did not alter depression, anxiety, resilience scores, or the levels of NSE and S100B.

Change in MoCA Scores and BDNF Levels
Values shown: Delta Value
MoCA (t-PBM)3.2
MoCA (Placebo)1.97
BDNF (t-PBM)821.94
BDNF (Placebo)359.41

Delta values for MoCA scores and BDNF levels in t-PBM and placebo groups.

What it means

Transcranial photobiomodulation increases cognitive function and BDNF levels in adults with MCI. It may serve as an adjunctive treatment to help prevent neurodegenerative diseases.

Limitations

The study had a dropout rate, with 76 out of 93 participants completing the study. The abstract does not specify other limitations.

“Transcranial photobiomodulation increases cognition and serum BDNF levels in adults over 50”— from the published abstract, J Photochem Photobiol B 2024

The paper at a glance

Magellan’s evidence labelnear-infrared light to cortex, BDNF (our label for this citation — see PubMed for the paper’s own title and authors)
JournalJ Photochem Photobiol B
Year2024
PMID39423445 ↗
DOI10.1016/j.jphotobiol.2024.113041 ↗
TopicBrain, cognition & mood

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Transcranial PBM Helmet

Targets age-related cognitive decline. Research relevant to this mechanism is indexed on PubMed and linked below; it describes the mechanism rather than this specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Can transcranial photobiomodulation (t-PBM) improve cognition, mood, and biomarker levels in individuals with mild cognitive impairment (MCI)? [Plain-English summary of J Photochem Photobiol B 2024, PMID 39423445, DOI 10.1016/j.jphotobiol.2024.113041]. Magellan Longevity. https://magellanlongevity.com/study/s159.html
BibTeX
@misc{magellan_s159, title = {Can transcranial photobiomodulation (t-PBM) improve cognition, mood, and biomarker levels in individuals with mild cognitive impairment (MCI)?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/s159.html}}, note = {Plain-English summary of PubMed PMID 39423445; DOI 10.1016/j.jphotobiol.2024.113041; J Photochem Photobiol B 2024. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/s159.html

Related studies in the Magellan library

All 26 Magellan summaries on brain, cognition & mood →

How this summary was made. Every section above restates what the published abstract of PMID 39423445 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.